ተጨማሪ መረጃ ― አማርኛ

Vitiligo(ቪቲሊጎ) በሜላኖይት እና በሌሎች ምክንያቶች የሚከሰት ነጭ ቆዳን የሚያመጣ ተለመደ የቆዳ በሽታ ነው። ቅርብ ጊዜ የተደረጉት ጥናቶች እንደሚያሳዩት፣ ይህ በራስን የመከላከል በሽታ ነው። ብዙውን ጊዜ የመዋቢያዎች ጉዳይ ተብሎ ይታያል፣ ነገር ግን የአእምሮ ደህንነትን እና ዕለታዊ ሕይወትን በጣም ሊጎዳ ይችላል። ኤ. ኤ. አ. በ2011 ዓ.ም. የሚታወቀውን segmental vitiligo ዓይነት ከሌሎች ተለይቶ ይገለጣል።
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.

ንቁ የቪቲሊጎ ሕመምተኞች ለሥርዓታዊ ግሉኮርቲሲዎች፣ ፎቶተራፒ እና ሥርዓታዊ የበሽታ መከላከያ መድሃኒቶች ብዙ የሕክምና አማራጮች አሉባቸው። ተረጋጋ የቪቲሊጎ ሕመምተኞች ከአካባቢያዊ ኮርቲሲዎች፣ ካልሲኒዩሪን አጋቾች፣ ፎቶተራፒ እና የንቅለተከላ ሂደቶች ጥቅም ሊያገኙ ይችላሉ። የ vitiligo መሰረታዊ ሂደቶችን በመረዳት ቅርብ ጊዜ የተሻለ እድገቶችን የሚያሳይ ህክምናዎች እንዲፈጠሩ ይረዳል። በአሁኑ ጊዜ JAK አጋቾች በጣም ተስፋ የሚሰጡ ናቸው፤ ጥሩ ተግባር እና ውጤታማ ውጤቶችን ይሰጣሉ። ነገርግን ከሌሎች የበሽታ መከላከያ ወኪሎች ጋር የተለመዱ ድብቅ ኢንፌክሽኖች እና የስርዓት ጎንደር ጉዳቶች አሉ። ቀጣይ ምርምር በ vitiligo እድገት (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) ውስጥ የሚሳተፉ ቁልፍ ሳይቶኪኖችን ለማለየት ይተግባር ነው። እነዚህን ሳይቶኪኖች ማገድ በእንስሳት ሞዴሎች እና በአንዳንድ ታካሚዎች ላይ ተስፋ ያሳየችው ነው። ተጨማሪ ምርምር በ miRNA-based therapeutics እና adoptive Treg cell therapy ላይ በሂደት ላይ ነው።
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.